Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Research ArticleOriginal Article
Open Access

Risk factors and characteristics of hospitalized COVID-19 patients in Jordan

Rashed O. Alqaisi, Waqar A. Al-Kubaisy, Shahed N. Abughanam, Areen Z. Alfalayleh and Mohamad-Said H. Almasri
Saudi Medical Journal October 2023, 44 (10) 1054-1060; DOI: https://doi.org/10.15537/smj.2023.44.20230209
Rashed O. Alqaisi
From the Department of Public Health (Al-Kubaisy), Mutah University, Al-Karak; and from Ministry of Health (Almasri, Alfalayleh, Abughanam), Irbid, Jordan.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rashed O. Alqaisi
  • For correspondence: [email protected]
Waqar A. Al-Kubaisy
From the Department of Public Health (Al-Kubaisy), Mutah University, Al-Karak; and from Ministry of Health (Almasri, Alfalayleh, Abughanam), Irbid, Jordan.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahed N. Abughanam
From the Department of Public Health (Al-Kubaisy), Mutah University, Al-Karak; and from Ministry of Health (Almasri, Alfalayleh, Abughanam), Irbid, Jordan.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Areen Z. Alfalayleh
From the Department of Public Health (Al-Kubaisy), Mutah University, Al-Karak; and from Ministry of Health (Almasri, Alfalayleh, Abughanam), Irbid, Jordan.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamad-Said H. Almasri
From the Department of Public Health (Al-Kubaisy), Mutah University, Al-Karak; and from Ministry of Health (Almasri, Alfalayleh, Abughanam), Irbid, Jordan.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

Objectives: To investigate the occurrence and identify the factors contributing to hospitalization among individuals diagnosed with COVID-19.

Methods: From June 15, 2020 to September 30, 2020, a cross-sectional study utilizing an online questionnaire was carried out in Jordan. The study included 657 COVID-19 patients who had recovered and had reached a minimum of 3 months post-illness. Sociodemographic and COVID-19-related data were collected. The questionnaire was distributed to members of the “My Experience with COVID-19 Association” in Jordan.

Results: The prevalence of hospitalization among COVID-19 patients was 3%. Patients with hypertension (p=0.00), diabetes mellitus (p=0.00), and heart disease (p=0.009); using angiotensin-converting enzyme inhibitors (ACE) and angiotensin-receptor blockers (ARBs) (p=0.00); with body mass indexes (BMI) above normal (p=0.005); and aged over 45 years (p=0.00) were at higher risk of hospitalization. Using an odds ratio (OR), hypertension (OR=7.1), diabetes mellitus (OR=11.4), heart disease (OR=6.3), angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers use (OR=10.8), and having a BMI >25 (OR=5) were significant hospitalization risk factors. The seasonal influenza vaccine, smoking, and neuropsychological symptoms showed no significance.

Conclusion: Identifying high-risk groups can help them monitor their health and take preventive measures against COVID-19 infection.

Keywords:
  • COVID-19
  • hospitalization
  • risk factors
  • drugs
  • comorbidity

In March 2020, the World Health Organization (WHO) officially declared the COVID-19 outbreak, caused by the SARS-CoV-2 virus, as a pandemic.1 Symptom severity in COVID-19 patients varies widely and remains poorly understood.2-4 While a large proportion of COVID-19 patients are asymptomatic, reported illnesses among symptomatic patients range from mild cold-like symptoms to severe illness and death.2 Fever, cough, and dyspnea are frequently cited as the most commonly reported symptoms among individuals infected with COVID-19.5,6

As a measure against the COVID-19 pandemic, the government of Jordan took decisive action by implementing a comprehensive statewide lockdown. This involved the temporary closure of educational institutions, prohibiting public gatherings, and imposing travel restrictions by shutting down borders and airports. These measures were put in place to effectively curb the rapid transmission of the virus.7 Consequently, at the time of this study, only a small number of COVID-19 cases were detected, and few patients were hospitalized. Notably, this study was conducted prior to the emergence of various COVID-19 variants.8

As the pandemic has advanced, numerous underlying medical conditions have been recognized as potential risk factors for COVID-19 hospitalization, encompassing various health conditions, including heart disease, diabetes, hypertension, and smoking.9,10 The worldwide smoking increase, including in Jordan, may be a risk factor for COVID-19 complications and hospitalization. Additionally, some medications—particularly angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs)—have been suspected in augmenting the pathogenicity of COVID-19.11 Conversely, a study carried out in the United Kingdom (UK) found that influenza vaccination was associated with significantly decrease risk of hospitalization in people diagnosed with COVID-19.12

However, most COVID-19 patients have mild symptoms and do not require hospitalization; many studies have focused solely on hospitalized patients, disregarding nonhospitalized patients. The objective of this study is to assess the prevalence of COVID-19 hospitalization and identify the risk factors associated with patients who require hospitalization due to COVID-19.

Methods

A systematic search method was employed to find relevant prior research on the topic. Extensive literature searches were conducted on reputable websites such as PubMed and the WHO to gather pertinent information. A cross-sectional, self-reported online survey was conducted to collect data from 657 individuals who had recovered from COVID-19 during the specified period from June 15, 2020 to September 30, 2020. The survey was administered in Arabic and made available through a web-based platform created using Google Forms. Participants were recruited from all 12 provinces of Jordan and were required to meet specific inclusion criteria, including being aged 18 or older, having tested positive for COVID-19 by PCR for the first time, and having no preexisting neurological or psychiatric conditions. Participants were recruited through the My Experience with COVID-19 Association, which has 28,000 recovered COVID-19 patients as members. They were reached through social media platforms. Ethical approval was obtained from the Ethics Committee, Mutah University, Al Karak, Jordan (approval no.: 1082023).

To ensure data completeness, participants were prompted to complete all questionnaire items before proceeding. Participants had the option to voluntarily withdraw from the study at any given point. The survey comprised 2 sections. The first section focused on sociodemographic information and COVID-19-related medical histories, and the second section focused on symptoms, severity, hospitalization, and the psychological effects of the disease. After 6 weeks, 657 completed surveys were collected and analyzed using descriptive statistics and inferential tests, such as the Chi-square, odds ratio (OR), and confidence interval (CI), with a p-value threshold of 0.05 for statistical significance. Data analysis was performed using the Statistical Package for the Social Sciences, Windows version 25.0 (IBM Corp., Armonk, NY).

Results

This study investigated the clinical and sociodemographic characteristics of 657 recovered COVID-19 patients in Jordan from 2020 to 2021. The patients had an average age of 30.55±11.9 years, ranging from 18 to 78 years. A small percentage (3%) of patients had a prior history of hospital admissions during their COVID-19 illness. Females accounted for 67.6% of the patient population, including 23 individuals who were pregnant. The majority of patients (77.6%) experienced at least one psychological symptom throughout the course of their illness (Table 1). Of the comorbidity diseases, 4.4% of the patients had diabetes mellitus, 6.4% had hypertension, 2% had heart disease, and 18% were smokers (Table 2). The study also found that hospitalization among COVID-19 patients was significantly related to several symptoms, including exhaustion, fever, shortness of breath, blurred vision, memory disturbance, cough, and speaking difficulty (Table 3). Patients ≥45 years showed a significantly higher hospitalization rate (11.5%) than patients who are younger than 45 (1.4%) year old. Overweight patients (normal BMI 18.5-24.9) also showed a significantly higher hospitalization rate (4.8%) during COVID-19 illness than patients with BMIs lower than 25 (1.2%) (Table 1). Significantly higher rates of admission were also detected among patients with a medical history of diabetes, hypertension, and cardiovascular disease. Patients taking ACEIs and ARBs were 10 times more likely to be admitted to the hospital during COVID-19 illness than the counter group (Table 2). However, other factors, such as the seasonal influenza vaccine, smoking, gender, and neuropsychological symptoms, showed no significant relationship to hospitalization risk (Table 1).

View this table:
  • View inline
  • View popup
Table 1

- Sociodemographic and clinical presentation of 657 recovered COVID-19 patients in Jordan 2020–2021.

View this table:
  • View inline
  • View popup
Table 2

- Relationship of the presence of comorbidities to hospital admission among COVID-19 patients.

View this table:
  • View inline
  • View popup
Table 3

- Symptoms of hospitalized and nonhospitalized COVID-19 patients.

Discussion

As of June 28, 2022, the global health has been greatly affected by the COVID-19 pandemic, resulting in a substantial number of cases, estimated at 767.51 million, and a significant death toll of approximately 6.94 million worldwide.13 The first case reported in Jordan was in March 2020; by August of the same year, only 1,208 cases had been reported in the country. This small number is attributed to the strict measures taken by the Jordanian government to effectively curb the transmission of the virus.7

This study found that the hospital admission rate for COVID-19 patients in Jordan was 3%, much lower than the UK’s 13% rate. The variation can be linked to the lockdown measures enforced by the Jordanian government and the country’s younger population compared to the UK’s population.14,15

We identified several common symptoms that were significant factors in COVID-19 patient hospital admission, including pulmonary symptoms, such as shortness of breath (OR=8.8); extrapulmonary symptoms, such as blurred vision (OR=3.4); and disturbances in speech or movement (OR=5.5). These findings are consistent with previous studies.16,17

We found that comorbidities, such as diabetes, heart disease, hypertension, and obesity, as well as certain medications used to treat hypertension (ACEIs and ARBs), were significant risk factors for hospital admission in COVID-19 patients. Our findings are consistent with previous studies.18-20 These comorbidities may interact with COVID-19 pathogenesis, potentially leading to severe illness. For example, individuals diagnosed with diabetes have a heightened susceptibility to developing severe cases of COVID-19 infection for reasons that include impaired immune responses, and coexisting complication, such as cardiovascular disease and obesity.21,22 These factors can result in prolonged symptomatology even after illness.23 Diabetes can also affect various organs and systems in the body, including the respiratory system, which can exacerbate COVID-19’s impact on the lungs. Moreover, hyperglycemia in patients with diabetes can cause the overproduction of proinflammatory cytokines, which can cause a cytokine storm, leading to increased COVID-19 severity.21 Hypertension may also contribute to severe COVID-19 illness due to the interaction between hypertension and arterial stiffness, which can lead to vascular damage, inflammation and finally calcification.24 Hypertension may additionally play a role in the emergence of diverse health conditions and complications, which are common in severe COVID-19 cases.25,26 Although some studies have suggested potential protective effects of ACEIs and ARBs on COVID-19 severity, others have reported conflicting results, indicating that the impact of these drugs remains controversial.27,28 Our study found that these medications were significant risk factors for hospital admission (OR=10.8, CI: 3.5–32.9), potentially due to up regulating the expression of ACE2 receptors in the respiratory tract, which are binding sites for the virus.29

Research indicates that advanced age is linked to a higher likelihood of experiencing severe illness caused by COVID-19. This association may be attributed to age-related alterations in the immune system, also known as immunosenescence.30 In addition, obesity is associated with impaired metabolic health and chronic inflammation, both of which have been implicated in increasing COVID-19’s severity. Obese individuals may also have reduced lung function and increased respiratory effort, potentially contributing to more severe disease outcomes.31

Surprisingly, we found no significant relationship between smoking and hospitalization despite the high smoking and e-cigarette use rates in Jordan.32 This finding is consistent with a study that failed to find a significant relationship between smoking and COVID-19 hospitalization.33 However, another study found a significant relationship between smoking and COVID-19 severity.34 It is possible that the dilatational effect of individuals with preexisting diseases and smoking cessation during the pandemic may decrease hospitalization odds.

Finally, we could not prove a significant relationship between receipt of the seasonal influenza vaccine and decreased hospitalization odds in our study. This finding is contrary to a study carried out in England.12 However, the low mean age of our study sample may have affected this result, as older individuals are more likely to receive the seasonal influenza vaccine.35 The findings of our epidemiological study shed light on factors that contribute to the risk of with COVID-19 hospitalizations. This research contributes to the existing body of knowledge by identifying several novel risk factors, including diabetes mellitus, hypertension, age, heart disease, and the use of ACEI and ARB medications, which are associated with a higher likelihood of hospitalization. These results have important implications for future research. Firstly, further investigations are needed to elucidate the underlying mechanisms through which these risk factors have a notable impact on the severity and ultimate outcome of COVID-19 cases. Additionally, future studies should explore interventions and preventive strategies that target these specific risk factors, with the aim of reducing the burden of COVID-19 hospitalizations.

Study limitations

The study’s limitations encompass the utilization of self-reported data, which introduces the potential for recall bias and social desirability bias. The survey was carried out online in Arabic, which could have excluded individuals without internet access or technology proficiency, resulting in a potentially biased sample. Additionally, the convenience sampling method used through a single association and social media recruitment may introduce selection bias.

In summary, our study offers valuable insights into the correlation between the characteristics of COVID-19 patients and the need for hospitalization. The analysis revealed significant associations between various risk factors and the likelihood of hospitalization among patients. These research findings have substantial relevance in the current pandemic landscape, providing crucial insights for clinical decision-making and guiding public health interventions. Notably, our findings uncovered several new and important aspects in the landscape of COVID-19 hospitalizations. For instance, we observed a significant association between the use of ACEI medications and an increased likelihood of hospitalization, which has not been extensively explored in prior studies.

Furthermore, our study emphasizes the significance of diabetes mellitus as a risk factor in predicting severe COVID-19 outcomes, making a noteworthy contribution to the existing knowledge base. By emphasizing these new and important aspects, our study broadens the understanding of COVID-19 risk factors and helps guide future research and clinical decision-making.

Acknowledgment

The authors gratefully acknowledge Scribendi (www.scribendi.com) for the English language editing services.

Footnotes

  • Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company.

  • Received June 25, 2023.
  • Accepted August 24, 2023.
  • Copyright: © Saudi Medical Journal

This is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.

References

  1. 1.↵
    World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. [Updated2023 March 11; Cited 2023 Jul 3]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
  2. 2.↵
    1. Wang Y,
    2. Wang Y,
    3. Chen Y,
    4. Qin Q
    . Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020; 92: 568–576.
    OpenUrlPubMed
  3. 3.
    1. Gao Z,
    2. Xu Y,
    3. Sun C,
    4. Wang X,
    5. Guo Y,
    6. Qiu S, et al.
    A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect 2021; 54: 12–16.
    OpenUrl
  4. 4.↵
    1. Wang Y,
    2. Liu Y,
    3. Liu L,
    4. Wang X,
    5. Luo N,
    6. Ling L
    . Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis 2020; 221: 1770–1774.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Garg S,
    2. Kim L,
    3. Whitaker M,
    4. O’Halloran A,
    5. Cummings C,
    6. Holstein R, et al.
    Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 458–464.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Chen N,
    2. Zhou M,
    3. Dong X,
    4. Qu J,
    5. Gong F,
    6. Han Y, et al.
    Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 5070–513.
    OpenUrl
  7. 7.↵
    Prime Minister’s website. Defense orders notifications [Updated Cited 2023 June 3]. Available from: https://www.pm.gov.jo/AR/List/%d8%a8%d9%84%d8%a7%d8%ba%d8%a7%d8%aa_%d8%a3%d9%88%d8%a7%d9%85%d8%b1_%d8%a7%d9%84%d8%af%d9%81%d8%a7%d8%b9
  8. 8.↵
    World Health Organization. Tracking SARS-CoV-2 variants; 2021 [Updated 2023; Cited 2023 July 3]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
  9. 9.↵
    1. Vahey GM,
    2. McDonald E,
    3. Marshall K,
    4. Martin SW,
    5. Chun H,
    6. Herlihy R, et al.
    Colorado investigation team. Risk factors for hospitalization among persons with COVID-19-Colorado. PLoS One 2021; 16: e0256917.
    OpenUrlPubMed
  10. 10.↵
    World Health Organization. WHO: Strengthened response to cardiovascular diseases. [Updated 20 May 2022; Cited 2023 June 3]. https://jordan.un.org/en/183019-strengthened-response-cardiovascular-diseases
  11. 11.↵
    1. Liabeuf S,
    2. Moragny J,
    3. Bennis Y, et al.
    Association between renin-angiotensin system inhibitors and COVID-19 complications. Eur Heart J Cardiovasc Pharmacother 2020: pvaa062.
  12. 12.↵
    1. Wilcox CR,
    2. Islam N,
    3. Dambha-Miller H
    . Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study [Erratum in: BMJ Open Respir Res. 2021; 8] [: PMID: 33664123; PMCID: PMC7934200]. BMJ Open Respir Res 2021; 8: e000857.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    World Health Organization. WHO Coronavirus Disease (COVID-19). [Updated 2023; Cited 2023 June 28]. Available from: https://covid19.who.int/
  14. 14.↵
    Public Health England. Coronavirus (COVID-19) in the UK. [Updated 2023; Cited 2023 February 28]. Available from: https://coronavirus.data.gov.uk/details/healthcare?areaType=overview&areaName=United%20Kingdom
  15. 15.↵
    Statista. Median age of the population in the United Kingdom from 1950 to 2021 (in years). [Updated 2023. Cited 2023 June 3]. Available from: https://www.statista.com/statistics/281288/median-age-of-the-population-of-the-uk/
  16. 16.↵
    1. Turan O,
    2. Mirici A,
    3. Duru Akçalı S,
    4. Turan PA,
    5. Batum Ö,
    6. Şengül A, et al.
    Characteristics of hospitalised COVID-19 patients and parameters associated with severe pneumonia. Int J Clin Pract 2021; 75: e14786.
    OpenUrl
  17. 17.↵
    1. Ousseiran ZH,
    2. Fares Y,
    3. Chamoun WT
    . Neurological manifestations of COVID-19: a systematic review and detailed comprehension. Int J Neurosci 2023; 133: 754–769.
    OpenUrl
  18. 18.↵
    1. Vahey GM,
    2. McDonald E,
    3. Marshall K,
    4. Martin SW,
    5. Chun H,
    6. Herlihy R, et al.
    Risk factors for hospitalization among persons with COVID-19-Colorado. PLoS One 2021; 16: e0256917.
    OpenUrlPubMed
  19. 19.
    1. Ko JY,
    2. Danielson ML,
    3. Town M,
    4. Derado G,
    5. Greenlund KJ,
    6. Kirley PD, et al.
    Risk factors for coronavirus disease 2019 (COVID-19)-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin Infect Dis 2021; 72: e695–e703.
    OpenUrlPubMed
  20. 20.↵
    1. Alrashed AA,
    2. Khan TM,
    3. Alhusseini NK,
    4. Asdaq SM,
    5. Enani M,
    6. Alosaimi B, et al.
    Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study. J Infect Public Health 2021; 14: 726–733.
    OpenUrl
  21. 21.↵
    1. Nassar M,
    2. Daoud A,
    3. Nso N,
    4. Medina L,
    5. Ghernautan V,
    6. Bhangoo H, et al.
    Diabetes Mellitus and COVID-19: review Article. Diabetes Metab Syndr 2021; 15: 102268.
    OpenUrl
  22. 22.↵
    1. Blonde L,
    2. Umpierrez GE,
    3. Reddy SS,
    4. McGill JB,
    5. Berga SL,
    6. Bush M, et al.
    American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 Update [Erratum in: Endocr Pract. 2023 Jan;29] [1] [:80-81. PMID: 35963508; PMCID: PMC10200071]. Endocr Pract 2022; 28: 923–1049.
    OpenUrl
  23. 23.↵
    1. Rizvi AA,
    2. Kathuria A,
    3. Al Mahmeed W,
    4. Al-Rasadi K,
    5. Al-Alawi K,
    6. Banach M, et al.
    Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complications 2022; 36: 108336.
    OpenUrlCrossRef
  24. 24.↵
    1. Safar ME,
    2. Asmar R,
    3. Benetos A,
    4. Blacher J,
    5. Boutouyrie P,
    6. Lacolley P, et al.
    French study group on arterial stiffness. interaction between hypertension and arterial stiffness. Hypertension 2018; 72: 796–805.
    OpenUrl
  25. 25.↵
    1. Chung MK,
    2. Zidar DA,
    3. Bristow MR,
    4. Cameron SJ,
    5. Chan T,
    6. Harding CV 3rd., et al.
    COVID-19 and cardiovascular disease: from bench to bedside. Circ Res 2021; 128: 1214–1236.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Messerli FH,
    2. Williams B,
    3. Ritz E
    . Essential hypertension. Lancet 2007; 370: 591–603.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Hippisley-Cox J,
    2. Young D,
    3. Coupland C,
    4. Channon KM,
    5. Tan PS,
    6. Harrison DA, et al.
    Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart 2020; 106: 1503–1511.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Agirbasli M
    . The effects of antihypertensive medications on severity and outcomes of COVID19. J Hum Hypertens 2022; 36: 875–879.
    OpenUrl
  29. 29.↵
    1. Danser AH,
    2. Epstein M,
    3. Batlle D
    . Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 2020; 75: 1382–1385.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Barbé-Tuana F,
    2. Funchal G,
    3. Schmitz CR,
    4. Maurmann RM,
    5. Bauer ME
    . The interplay between immunosenescence and age-related diseases. Semin Immunopathol 2020; 42: 545–557.
    OpenUrlCrossRef
  31. 31.↵
    1. Murugan AT,
    2. Sharma G
    . Obesity and respiratory diseases. Chron Respir Dis 2008; 5: 233–242.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Al-Tammemi AB
    . Tobacco epidemic in Jordan: the time to act is now. Glob Health Promot 2022; 29: 97–101.
    OpenUrl
  33. 33.↵
    1. Farsalinos K,
    2. Bagos PG,
    3. Giannouchos T,
    4. Niaura R,
    5. Barbouni A,
    6. Poulas K
    . Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct J 2021; 18: 9.
    OpenUrl
  34. 34.↵
    1. Patanavanich R,
    2. Glantz SA
    . Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res 2020; 22: 1653–1656.
    OpenUrlCrossRefPubMed
  35. 35.↵
    GOV.UK. Flu vaccines for the 2023 to 2024 season. [Updated 2023; Cited in 2023 June 3]. Available from: https://www.gov.uk/government/publications/flu-vaccines-for-the-current-season/flu-vaccines-for-the-2023-to-2024-season#eligible-groups [Accessed July 3, 2023]
PreviousNext
Back to top

In this issue

Saudi Medical Journal: 44 (10)
Saudi Medical Journal
Vol. 44, Issue 10
1 Oct 2023
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Risk factors and characteristics of hospitalized COVID-19 patients in Jordan
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
Risk factors and characteristics of hospitalized COVID-19 patients in Jordan
Rashed O. Alqaisi, Waqar A. Al-Kubaisy, Shahed N. Abughanam, Areen Z. Alfalayleh, Mohamad-Said H. Almasri
Saudi Medical Journal Oct 2023, 44 (10) 1054-1060; DOI: 10.15537/smj.2023.44.20230209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Risk factors and characteristics of hospitalized COVID-19 patients in Jordan
Rashed O. Alqaisi, Waqar A. Al-Kubaisy, Shahed N. Abughanam, Areen Z. Alfalayleh, Mohamad-Said H. Almasri
Saudi Medical Journal Oct 2023, 44 (10) 1054-1060; DOI: 10.15537/smj.2023.44.20230209
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Exploring communication challenges with children and parents among pharmacists in Saudi Arabia
  • Exploring hypothyroidism’s effects on lipid profiles
  • Assessment of asthma control levels in a tertiary hospital
Show more Original Article

Similar Articles

Keywords

  • COVID-19
  • hospitalization
  • risk factors
  • drugs
  • comorbidity

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire